Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Williams

Internal Medicine Massillon, OH Medical Doctor

NPI 1508862343 CMS profile 23118

2458 Lincoln Way E, Massillon, OH 44646

Open in the dashboard

General payments

$12,594

796 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Williams of Massillon, OH is reported in the CMS Open Payments database as having received $12,594 across 796 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,035 113
2024 General $1,782 92
2023 General $1,905 91
2022 General $2,039 130
2021 General $1,971 129
2020 General $1,006 69
2019 General $1,855 172

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Williams
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Scott Williams were reported at $2,035. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Scott Williams Internal Medicine median Middle half National median
2019 $1,855 $159 $48–$570 $163
2020 $1,006 $119 $33–$402 $114
2021 $1,971 $135 $37–$521 $132
2022 $2,039 $141 $42–$496 $149
2023 $1,905 $149 $45–$519 $160
2024 $1,782 $154 $47–$537 $164
2025 $2,035 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,844 60 payments
  2. Novo Nordisk Inc $1,096 83 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $767 59 payments
  4. Lilly USA, LLC $766 52 payments
  5. AbbVie, Inc. $672 41 payments
  6. Pfizer Inc. $606 50 payments
  7. Novartis Pharmaceuticals Corporation $579 46 payments
  8. Janssen Pharmaceuticals, Inc $540 73 payments
  9. Merck Sharp & Dohme Corporation $476 40 payments
  10. Amarin Pharma Inc. $417 44 payments
  11. Other $3,830 248 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,477 789 payments
  2. Education $117 7 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,947 34 payments
  2. BREZTRI $1,426 9 payments
  3. Ozempic $957 71 payments
  4. RYBELSUS $696 57 payments
  5. AIRSUPRA $663 16 payments
  6. XARELTO $540 73 payments
  7. JARDIANCE $508 38 payments
  8. ENTRESTO $422 38 payments
  9. SYMBICORT $389 4 payments
  10. SUBLOCADE $369 29 payments
  11. Other $10,559 726 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 175 drugs

Part D claims

12,785

Median for Internal Medicine: 777

Drug cost

$1,145,368

Median for Internal Medicine: $73,373

Branded share of claims

21.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 334 $221,510
Eliquis Apixaban Brand 195 $132,597
Ozempic Semaglutide Brand 74 $98,168
Xarelto Rivaroxaban Brand 119 $81,011
Trulicity Dulaglutide Brand 40 $60,857
Farxiga Dapagliflozin Propanediol Brand 56 $58,966
Austedo Deutetrabenazine Brand 31 $54,057
Januvia Sitagliptin Phosphate Brand 56 $51,080
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 53 $46,186
Entresto Sacubitril/Valsartan Brand 30 $29,786

The 10 drugs with the highest cost, of 175 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$68,434

Of which drugs: $5,005

Medicare patients

246

Average age 73

Services billed

1,083

122 women, 124 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 37%
Ischemic heart disease 36%
Chronic kidney disease 33%
Depression 31%
Heart failure 27%
COPD 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 28 28 $2,291
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 100 $66

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $236
$236 — —
MOUNJARO
  • Lilly USA, LLC $108
$108 16 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $99
$99 56 —
RYBELSUS
  • Novo Nordisk Inc $90
$90 — —
Ozempic
  • Novo Nordisk Inc $90
$90 74 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

796 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record